Trilaciclib for early-stage HR-negative breast cancer after surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with early-stage breast cancer that is hormone receptor-negative (ER-negative and PR-negative) and either HER2-negative or HER2-positive.
- Your cancer was removed by surgery, and you have not had any chemotherapy, targeted therapy, immunotherapy, or radiation before surgery.
- You have either cancer in your lymph nodes or a tumor larger than 2 cm.
- You start the trial within 60 days after your surgery.
- You are in good overall health with normal blood counts, liver, kidney, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy. It is for people with several types of advanced solid tumors who will receive a specific chemo combination (paclitaxel plus carboplatin) for the first time.
This trial tests whether adding trilaciclib to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. It’s for patients who are starting treatment for the first time and can safely receive pre-surgery chemotherapy.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.